Anne Nalunkuma-Kazibwe

Anne Nalunkuma-Kazibwe

Auto-generated profile, based on publicly available information

Anne Nalunkuma-Kazibwe

School of Veterinary Medicine, Makerere University, P.O. Box 7062, Kampala, Uganda

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2011 in Future Microbiology
Verified
Journal Article
Closed access
MBMichael P. Barrett
Michael P. Barrett
IVIsabel Vincent
Isabel Vincent
RBRichard Burchmore
Richard Burchmore
AKAnne Jn Kazibwe
Anne Jn Kazibwe
EMEnock Matovu
Enock Matovu
Human African trypanosomiasis or ‘sleeping sickness’ is a neglected tropical disease caused by the parasite Trypanosoma brucei. A decade of intense international cooperation has brought the inciden...

1 July 2011 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
ITIbrahim A. Teka
Ibrahim A. Teka
AKAnne J. N. Kazibwe
Anne J. N. Kazibwe
NENasser El-Sabbagh
Nasser El-Sabbagh
MAMohammed I. Al-Salabi
Mohammed I. Al-Salabi
CWChristopher P. Ward
Christopher P. Ward
HKHarry De Koning
Harry De Koning
African trypanosomiasis is a disease of humans and livestock in many areas south of the Sahara. Resistance to the few existing drugs is a major impediment to the control of these diseases, and we investigated how resistance to the main veterinary drug diminazene aceturate correlates with changes in drug transport in resistant strains. The strain tbat1(−/−), lacking the TbAT1/P2 aminopurine transporter implicated previously in diminazene transport, was adapted to higher levels of diminazene resistance. The resulting cell line was designated ABR and was highly cross-resistant to other diamidines and moderately resistant to cymelarsan. Procyclic trypanosomes were shown to be a convenient model to study diamidine uptake in Trypanosoma brucei brucei given the lack of TbAT1/P2 and a 10-fold higher activity of the high-affinity pentamidine transporter (HAPT1). Diminazene could be transported by HAPT1 in procyclic trypanosomes. This drug transport activity was lacking in the ABR line, as reported previously for the pentamidine-adapted line B48. The Km for diminazene transport in bloodstream tbat1(−/−) trypanosomes was consistent with uptake by HAPT1. Diminazene transport in ABR and B48 cells was reduced compared with tbat1(−/−), but their resistance phenotype was different: B48 displayed higher levels of resistance to pentamidine and the melaminophenyl arsenicals, whereas ABR displayed higher resistance to diminazene. These results establish a loss of HAPT1 function as a contributing factor to diminazene resistance but equally demonstrate for the first time that adaptations other than those determining the initial rates of drug uptake contribute to diamidine and arsenical resistance in African trypanosomes.

1 December 2004 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
ATAmbrose O. Talisuna
Ambrose O. Talisuna
ANAnne Nalunkuma-Kazibwe
Anne Nalunkuma-Kazibwe
PLPeter Langi
Peter Langi
TMTheonest K. Mutabingwa
Theonest K. Mutabingwa
WWWilliam W. Watkins
William W. Watkins
UDUmberto D’alessandro
Umberto D’alessandro

3 February 2004 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
ATAmbrose O. Talisuna
Ambrose O. Talisuna
ANAnne Nalunkuma‐Kazibwe
Anne Nalunkuma‐Kazibwe
NBNathan Bakyaita
Nathan Bakyaita
PLPeter Langi
Peter Langi
TMTheonest K. Mutabingwa
Theonest K. Mutabingwa
TEThomas G. Egwang
Thomas G. Egwang
The rapid development of falciparum resistance to sulphadoxine–pyrimethamine (SP) in East and Central Africa has raised concerns as to the efficacy of combining it with another drug. In 2002, we assessed the efficacy of SP alone and combined with amodiaquine (AQ/SP) or chloroquine (CQ/SP) in Ugandan children with uncomplicated falciparum malaria. At day 14, adequate clinical response was 100% (84/84) for AQ/SP, 93% (92/101) for CQ/SP and 91% (73/80) for SP. At day 28, parasitological failure (RI–RIII) occurred in 16% (13/80) of children treated with AQ/SP, in 48% (48/100) of those treated with CQ/SP and in 61% (48/79) of those treated with SP alone. Compared with the AQ/SP arm, the odds for parasitological failure at day 28 were five times higher (95% CI, 2–10) in the CQ/SP group and sevenfold higher (95% CI, 3–17) in that of SP alone. CQ/SP does not offer any significant added benefit over SP alone while AQ/SP is an efficacious low‐cost combination. These findings have important policy implications for Uganda and other resource‐constrained African countries faced with the problematic choice of a new first‐line antimalarial treatment in a context of high CQ resistance.

29 September 2009 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
AKAnne J. N. Kazibwe
Anne J. N. Kazibwe
BNBarbara Nerima
Barbara Nerima
HKHarry De Koning
Harry De Koning
PMPascal Mäser
Pascal Mäser
MBMichael P. Barrett
Michael P. Barrett
EMEnock Matovu
Enock Matovu
The development of arsenical and diamidine resistance in Trypanosoma brucei is associated with loss of drug uptake by the P2 purine transporter as a result of alterations in the corresponding T. brucei adenosine transporter 1 gene (TbAT1). Previously, specific TbAT1 mutant type alleles linked to melarsoprol treatment failure were significantly more prevalent in T. b. gambiense from relapse patients at Omugo health centre in Arua district. Relapse rates of up to 30% prompted a shift from melarsoprol to eflornithine (α-difluoromethylornithine, DFMO) as first-line treatment at this centre. The aim of this study was to determine the status of TbAT1 in recent isolates collected from T. b. gambiense sleeping sickness patients from Arua and Moyo districts in Northwestern Uganda after this shift in first-line drug choice. Blood and cerebrospinal fluids of consenting patients were collected for DNA preparation and subsequent amplification. All of the 105 isolates from Omugo that we successfully analysed by PCR-RFLP possessed the TbAT1 wild type allele. In addition, PCR/RFLP analysis was performed for 74 samples from Moyo, where melarsoprol is still the first line drug; 61 samples displayed the wild genotype while six were mutant and seven had a mixed pattern of both mutant and wild-type TbAT1. The melarsoprol treatment failure rate at Moyo over the same period was nine out of 101 stage II cases that were followed up at least once. Five of the relapse cases harboured mutant TbAT1, one had the wild type, while no amplification was achieved from the remaining three samples. The apparent disappearance of mutant alleles at Omugo may correlate with melarsoprol withdrawal as first-line treatment. Our results suggest that melarsoprol could successfully be reintroduced following a time lag subsequent to its replacement. A field-applicable test to predict melarsoprol treatment outcome and identify patients for whom the drug can still be beneficial is clearly required. This will facilitate cost-effective management of HAT in rural resource-poor settings, given that eflornithine has a much higher logistical requirement for its application. Human African trypanosomiasis (HAT) manifests as a chronic infection caused by Trypanosoma brucei gambiense, or as a more acute form due to T. b. rhodesiense. Both manifestations occur in Uganda and melarsoprol use against the former was jeopardised in the 1990s as reports of reduced efficacy increased to the point where it was dismissed as first-line treatment at some treatment centers. Previous work to elucidate possible mechanisms leading to melarsoprol resistance pointed to a P2 type adenosine transporter known to mediate melarsoprol uptake and previously shown to be mutated in significant numbers of patients not responding to the drug. Our present findings indicate that there is a low prevalence of mutants in foci where melarsoprol relapses are infrequent. In addition we observe that at the Omugo focus where the drug was withdrawn as first line over 6 years ago, the mutant alleles have disappeared, suggesting that drug pressure is responsible for fuelling their spread. Thus constant monitoring for mutants could play a key role in cost-effective HAT management by identifying which foci can still use the less logistically demanding melarsoprol as opposed to the alternative drug eflornithine. What is required now is a simple method for identifying such mutants at the point of care, enabling practitioners to make informed prescriptions at first diagnosis.

27 March 2012 in Journal of Tropical Medicine
Verified
Journal Article
Open access
PDF file
EMEnock Matovu
Enock Matovu
AKAnne Juliet Kazibwe
Anne Juliet Kazibwe
CMClaire Mack Mugasa
Claire Mack Mugasa
JNJoseph Mathu Ndungu
Joseph Mathu Ndungu
ZNZablon Kithingi Njiru
Zablon Kithingi Njiru
Human African trypanosomiasis is a debilitating disease prevalent in rural sub-Saharan Africa. Control of this disease almost exclusively relies on chemotherapy that should be driven by accurate diagnosis, given the unacceptable toxicity of the few available drugs. Unfortunately, the available diagnostics are characterised by low sensitivities due to the inherent low parasitaemia in natural infections. Demonstration of the trypanosomes in body fluids, which is a prerequisite before treatment, often follows complex algorithms. In this paper, we review the available diagnostics and explore recent advances towards development of novel point-of-care diagnostic tests.